

CLAIMS



- 1. A method for protecting an animal from cytotoxic side effects of the administration of a mitotic phase cell cycle inhibitor or a topoisomerase inhibitor comprising administering to the animal, in advance of administration of said inhibitor, an effective amount of at least one cytoprotective of B unsaturated aryl sulfone compound.
- 2. A method according to claim 1 wherein the cytoprotective compound has the formula I:

$$Q_1 = CH = CH$$

$$Q_2 = CH = CH$$

$$Q_2 = CH$$

$$Q_3 = CH$$


wherein:

n is one or zero;

 $\ensuremath{\text{Q}}_1$ and $\ensuremath{\text{Q}}_2$ are, same or different, are substituted or unsubstituted aryl; or

a pharmaceutically acceptable salt thereof.

- 3. The method according to claim 2 wherein:
- Q₁ is selected from the group consisting of substituted and unsubstituted phenyl, 1-naphthyl, 2-naphthyl, 9-anthryl and an aromatic radical of formula II:



wherein


n, is 1 or 2,

Y₁ and Y₂ are independently selected from the group consisting of hydrogen, halogen, and nitro, and

 \mathbf{X}_1 is selected from the group consisting of oxygen, nitrogen, sulfur and

$$S_{O}^{O}$$
; and

Q₂ is selected from the group consisting of substituted and unsubstituted phenyl, 1-naphthyl, 2-naphthyl, 9-anthryl and an aromatic radical of formula III:



wherein

 n_2 is 1 or 2,

Y₃ and Y₄ are independently selected from the group consisting of hydrogen, halogen, and nitro, and

 X_2 , X_3 and X_4 are independently selected from the group consisting of carbon, oxygen, nitrogen, sulfur and

provided that not all of X_2 , X_3 and X_4 may be carbon; or a pharmaceutically acceptable salt thereof.



A compound according to claim 3 wherein Q_1 and Q_2 are selected from substituted and unsubstituted phenyl.

5. A method according to claim 4 wherein the cytoprotective compound has the formula IV:

$$\begin{array}{c} R_{2} \\ R_{3} \\ R_{4} \\ R_{5} \\ R_{6} \\ R_{7} \\ R_{8} \\ R_{8} \\ \end{array} \begin{array}{c} R_{10} \\ R_{10} \\ R_{8} \\ \end{array}$$

wherein:

R₁ through R₁₀ are independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, C1-C8 alkoxy, nitro, cyano, carboxy, hydroxy, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) C1-C6 trifluoroalkoxy and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

6. The method according to claim 4 wherein the cytoprotective compound has the formula V:

$$\begin{array}{c|c}
R_2 & O & V \\
\hline
-CH_2 - S = O & CH = CH \\
\hline
R_1 & & & & \\
\hline
R_3 - & & & & \\
\hline
R_4 & & & & \\
\hline
R_5 - & & & & \\
\hline
R_6 & & & & & \\
\hline
R_7 - & & & & & \\
\hline
R_7 - & & & & & \\
\hline
R_8 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & \\
\hline
R_9 - & & & & & \\
\hline
R_9 - & & & & \\
\hline
R_9 - & &$$

wherein R₁, R₂, R₃ and R₄ are independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, C1-C8 alkoxy, nitro, cyano, carboxy, hydroxy and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

- 7. The method of claim 6 wherein the cytoprotective compound is selected from the group consisting of (E)-4-fluorostyryl-4-\(C)-4-chlorobenzylsulfone; (E)-2-chloro-4-fluorostyryl-4-chlorobenzylsulfone; (E)-4-carboxystyryl-4-chlorobenzyl sulfone; and (E)-4-fluorostyryl-2,4-dichlorobenzylsulfone.
- 8. The method according to claim 1 wherein the oytoprotective compound is according to formula VI:

$$R_1$$
 R_2
 R_1
 R_2
 R_3
 R_4
 R_4

wherein:

 R_1 , R_2 , R_3 and R_4 are independently selected from the group consisting of hydrogen, halogen, (1-C8) alkyl, C1-C8 alkoxy, nitro, cyano, carboxy, hydroxy and trifluoromethyl;


or a pharmaceutically acceptable salt thereof.

9. The method according to claim 1 wherein the cytoprotective compound is according to formula VII:

wherein

 Q_3 , Q_4 and Q_5 are independently selected from the group consisting of phenyl and mono-, di-, tri-, tetra- and penta-substituted phenyl where the substituents, which may be the same or different, are independently selected from the group consisting of halogen, C1-C8 alkyl, C1-C8 alkoxy, nitro, cyano, carboxy, hydroxy, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), C1-C6 trifluoroalkoxy and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

10. The method according to claim 9 wherein the cytoprotective compound is according to formula VIIa:



wherein

 R_1 and R_2 are independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, C1-8 alkoxy, nitro, cyano, carboxy, hydroxy, and trifluoromethyl; and

R₃ is selected from the group consisting of unsubstituted phenyl, mono-substituted phenyl and di-substituted phenyl, the substituents on the phenyl ring being independently selected from the group consisting of halogen and C1-8 alkyl; or a pharmaceutically acceptable salt thereof.

The method of claim 10 wherein the cytoprotective compound is 2-(phenylsulfonyl)-1-phenyl-3-(4-fluorophenyl)-2-propen-1-one.

- 60 -

280027/DAM

- 12. The method of claim 1 wherein the cytoprotective compound is of the Z-configuration.
- 13. The method according to claim 1 wherein the cytoprotective compound is administered at least about 4 hours before administration of the mitotic phase cell cycle inhibitor or topoisomerase inhibitor.



- 14. The method according to claim 13 wherein the cytoprotective compound is administered at least about 12 hours before administration of the mitotic phase cell cycle inhibitor or topoisomerase inhibitor.
- 15. The method according to claim 14 wherein the cytoprotective compound is administered at least about 24 hours before administration of the mitotic phase cell cycle inhibitor or topoisomerase inhibitor.
- 16. The method according to claim 13 wherein the mitotic phase cell cycle inhibitor is selected from the group consisting of vinca alkaloids, taxanes, naturally occurring macrolides, and colchicine and its derivatives; and the topoisomerase inhibitor is selected from the group consisting of camptothecin, etoposide and mitoxantrone.
- 17. The method according to claim 16 wherein the mitotic phase cell cycle inhibitor is selected from the group consisting of paclitaxel and vincristine.



18. A method for treating cancer or other proliferative disorder comprising administering to an animal an effective amount at least one cytoprotective α,β unsaturated aryl sulfone compound followed by an effective amount of at least one mitotic phase cell cycle inhibitor or topoisomerase inhibitor after administration of the cytoprotective α,β unsaturated aryl sulfone compound.

- 19. The method according to claim 18 wherein the cytoprotective compound is administered at least about 4 hours before administration of the mitotic phase cell cycle inhibitor or topoisomerase inhibitor.
- 20. The method according to claim 19 wherein the cytoprotective compound is administered at least about 12 hours before administration of the mitotic phase cell cycle inhibitor or topoisomerase inhibitor.
- 21. The method according to claim 20 wherein the cytoprotective compound is administered at least about 24 hours before administration of the mitotic phase cell cycle inhibitor or topoisomerase inhibitor.
- The method of claim 18 wherein the cytoprotective compound is selected from the group consisting of (E)-4-fluorostyryl-4-chlorobenzylsulfone; (E)-2-chloro-4-fluorostyryl-4-chlorobenzylsulfone; (E)-4-carboxystyryl-4-chlorobenzyl sulfone; and (E)-4-fluorostyryl-2,4-dichlorobenzylsulfone.

